Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 14, Issue 12, Pages 1349-1363Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2014.987131
Keywords
Brintellix((R)); clinical studies; efficacy and safety; Lu AA21004; major depression; serotonin receptors; serotonin transporters; vortioxetine
Categories
Ask authors/readers for more resources
Vortioxetine (Lu AA21004; Brintellix((R))) has received approval from various international regulatory agencies for the treatment of major depression. The drug molecule has a multimodal mechanism of action that projects it as a unique molecule for the treatment of major depression. These mechanisms include property to inhibit serotonin reuptake via inhibiting serotonin transporters and acting on multiple serotonin receptor subtypes. Vortioxetine is an agonist of 5-HT1A, a partial agonist of 5-HT1B and an antagonist of 5-HT1D, 5-HT3 and 5-HT7 serotoninergic receptors. The molecule has been found to be effective and well-tolerable to be administered in humans for the treatment of major depression. Precautions should be exercised when vortioxetine is prescribed with cytochrome P450 inducers and inhibitors. This review attempts to compile the efficacy profile of vortioxetine in different clinical trials and the results are compared with other standard antidepressants.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available